Details of the Drug Combination

General Information of Drug Combination (ID: DCPG3DT)

Drug Combination Name
Amonafide Triapine
Indication
Disease Entry Status REF
Glioma Investigative [1]
Component Drugs Amonafide   DMAH59S Triapine   DM7XZY5
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: SF-268
Zero Interaction Potency (ZIP) Score: 6.03
Bliss Independence Score: 8.95
Loewe Additivity Score: 2.59
LHighest Single Agent (HSA) Score: 8.47

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Amonafide
Disease Entry ICD 11 Status REF
Breast cancer 2C60-2C65 Phase 3 [2]
Ovarian cancer 2C73 Phase 3 [2]
Prostate cancer 2C82.0 Phase 3 [2]
Indication(s) of Triapine
Disease Entry ICD 11 Status REF
Nerve injury ND56.4 Phase 2 [3]
Triapine Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Ribonucleoside-diphosphate reductase M2 (RRM2) TTBWDI0 RIR2_HUMAN Modulator [3]
------------------------------------------------------------------------------------
Triapine Interacts with 2 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Histone H2AX (H2AX) OT18UX57 H2AX_HUMAN Increases Expression [5]
Thioredoxin-dependent peroxide reductase, mitochondrial (PRDX3) OTLB2WEU PRDX3_HUMAN Increases Oxidation [4]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Adenocarcinoma DC11F50 NCIH23 Investigative [1]
Adenocarcinoma DCYYEQR A549 Investigative [1]
Adenocarcinoma DCWCNLL SW-620 Investigative [1]
Adult T acute lymphoblastic leukemia DCDH70M MOLT-4 Investigative [1]
Anaplastic large cell lymphoma DCTJUF2 SR Investigative [1]
Clear cell renal cell carcinoma DCOHW11 786-0 Investigative [1]
Clear cell renal cell carcinoma DC73HSD TK-10 Investigative [1]
Clear cell renal cell carcinoma DC3B45C CAKI-1 Investigative [1]
Glioma DCQOHC3 SF-539 Investigative [1]
Large cell lung carcinoma DCYW2H2 NCI-H460 Investigative [1]
Non-small cell lung carcinoma DCYPUON HOP-92 Investigative [1]
Carcinoma DCMRT5G MCF7 Investigative [6]
Invasive ductal carcinoma DCFV8VG BT-549 Investigative [6]
------------------------------------------------------------------------------------
⏷ Show the Full List of 13 DrugCom(s)

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 ClinicalTrials.gov (NCT00715637) Phase III Randomized Study of Amonafide (AS1413) and Cytarabine Versus Daunorubicin and Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- the ACCEDEStudy. U.S. National Institutes of Health.
3 PAN-811 inhibits oxidative stress-induced cell death of human Alzheimer's disease-derived and age-matched olfactory neuroepithelial cells via suppression of intracellular reactive oxygen species. J Alzheimers Dis. 2009;17(3):611-9.
4 The iron-chelating drug triapine causes pronounced mitochondrial thiol redox stress. Toxicol Lett. 2011 Mar 5;201(2):130-6. doi: 10.1016/j.toxlet.2010.12.017. Epub 2010 Dec 31.
5 Distinct mechanisms of cell-kill by triapine and its terminally dimethylated derivative Dp44mT due to a loss or gain of activity of their copper(II) complexes. Biochem Pharmacol. 2014 Oct 1;91(3):312-22. doi: 10.1016/j.bcp.2014.08.006. Epub 2014 Aug 15.
6 Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.